{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T08:52:42Z","timestamp":1773564762050,"version":"3.50.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.1038\/nri802","type":"journal-article","created":{"date-parts":[[2004,5,24]],"date-time":"2004-05-24T20:57:44Z","timestamp":1085432264000},"page":"364-371","source":"Crossref","is-referenced-by-count":543,"title":["Development of anti-TNF therapy for rheumatoid arthritis"],"prefix":"10.1038","volume":"2","author":[{"given":"Marc","family":"Feldmann","sequence":"first","affiliation":[]}],"member":"297","reference":[{"key":"BFnri802_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0378-1119(80)90138-9","volume":"10","author":"T Taniguchi","year":"1980","unstructured":"Taniguchi, T., Ohno, S., Fujii-Kuriyama, Y. & Muramatsu, H. The nucleotide sequence of human fibroblast interferon cDNA. Gene 10, 11\u201315 (1980).","journal-title":"Gene"},{"key":"BFnri802_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/284316a0","volume":"284","author":"S Nagata","year":"1980","unstructured":"Nagata, S. et al. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 284, 316\u2013320 (1980).","journal-title":"Nature"},{"key":"BFnri802_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/295503a0","volume":"295","author":"PW Gray","year":"1982","unstructured":"Gray, P. W. et al. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature 295, 503\u2013508 (1982).","journal-title":"Nature"},{"key":"BFnri802_CR4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/312721a0","volume":"312","author":"PW Gray","year":"1984","unstructured":"Gray, P. W. et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumor-necrosis factor activity. Nature 312, 721\u2013724 (1984).","journal-title":"Nature"},{"key":"BFnri802_CR5","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/312724a0","volume":"312","author":"D Pennica","year":"1984","unstructured":"Pennica, D. et al. Human tumor-necrosis factor: precursor structure expression and homology to lymphotoxin. Nature 312, 724\u2013729 (1984).","journal-title":"Nature"},{"key":"BFnri802_CR6","volume-title":"Cytokine Reference","author":"JJ Oppenheim","year":"2001","unstructured":"Oppenheim, J. J. & Feldmann, M. E. Cytokine Reference, Vol 1: Ligands (Academic Press, London, 2001) http:\/\/www.apnet.com\/cytokinereference"},{"key":"BFnri802_CR7","first-page":"CD003266","volume":"4","author":"J Cody","year":"2001","unstructured":"Cody, J. et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Sys. Rev. 4, CD003266 (2001).","journal-title":"Cochrane Database Sys. Rev."},{"key":"BFnri802_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000046557","volume":"105","author":"G Morstyn","year":"2001","unstructured":"Morstyn, G., Foote, M. A., Walker, T. & Molineux, G. Filgrastim (r-metHuG-CSF) in the 21st century: SD\/01. Acta Haematol. 105, 151\u2013155 (2001).","journal-title":"Acta Haematol."},{"key":"BFnri802_CR9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00003086-199101000-00002","volume":"262","author":"WB Coley","year":"1991","unstructured":"Coley, W. B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin. Orthop. 262, 3\u201311 (1991).","journal-title":"Clin. Orthop."},{"key":"BFnri802_CR10","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","volume":"72","author":"EA Carswell","year":"1975","unstructured":"Carswell, E. A. et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 72, 3666\u20133670 (1975).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri802_CR11","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/S0021-9258(18)89560-6","volume":"260","author":"BB Aggarwal","year":"1985","unstructured":"Aggarwal, B. B. et al. Human tumor-necrosis factor production, purification and characterization. J. Biol. Chem. 260, 2345\u20132354 (1985).","journal-title":"J. Biol. Chem."},{"key":"BFnri802_CR12","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1126\/science.3895437","volume":"229","author":"B Beutler","year":"1985","unstructured":"Beutler, B., Milsark, I. W. & Cerami, A. C. Passive immunization against cachectin\/tumor-necrosis factor protects mice from lethal effect of endotoxin. Science 229, 869\u2013871 (1985).","journal-title":"Science"},{"key":"BFnri802_CR13","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","volume":"358","author":"DM Lee","year":"2001","unstructured":"Lee, D. M. & Weinblatt, M. E. Rheumatoid arthritis. Lancet 358, 903\u2013911 (2001).","journal-title":"Lancet"},{"key":"BFnri802_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","volume":"322","author":"ED Harris Jr.","year":"1990","unstructured":"Harris, E. D. Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med. 322, 1277\u20131289 (1990).","journal-title":"N. Engl. J. Med."},{"key":"BFnri802_CR15","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.4049\/jimmunol.152.8.4149","volume":"152","author":"AE Koch","year":"1994","unstructured":"Koch, A. E. et al. Vascular endothelial growth factor. A cytokine-modulating endothelial function in rheumatoid arthritis. J. Immunol. 152, 4149\u20134156 (1994).","journal-title":"J. Immunol."},{"key":"BFnri802_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/BF00541245","volume":"2","author":"A Fontana","year":"1982","unstructured":"Fontana, A. et al. Interleukin-1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol. Int. 2, 49\u201353 (1982).","journal-title":"Rheumatol. Int."},{"key":"BFnri802_CR17","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.4049\/jimmunol.138.10.3213","volume":"138","author":"FS Di Giovine","year":"1987","unstructured":"Di Giovine, F. S., Malawista, S. E., Nuki, G. & Duff, G. W. Interleukin-1 (IL-1) as a mediator of crystal arthritis. Stimulation of T-cell and synovial fibroblast mitogenesis by urate crystal-induced IL-1. J. Immunol. 138, 3213\u20133218 (1987).","journal-title":"J. Immunol."},{"key":"BFnri802_CR18","first-page":"449","volume":"73","author":"G Buchan","year":"1988","unstructured":"Buchan, G., Barrett, K., Turner, M., Chantry, D., Maini, R. N. & Feldmann, M. Interleukin-1 and tumour-necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1\u03b1. Clin. Exp. Immunol. 73, 449\u2013455 (1988).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnri802_CR19","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/art.1780340908","volume":"34","author":"CQ Chu","year":"1991","unstructured":"Chu, C. Q., Field, M., Feldmann, M. & Maini, R. N. Localization of tumor-necrosis factor-\u03b1 in synovial tissues and at the cartilage\u2013pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34, 1125\u20131132 (1991).","journal-title":"Arthritis Rheum."},{"key":"BFnri802_CR20","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/art.1780310816","volume":"31","author":"T Saxne","year":"1988","unstructured":"Saxne, T., Palladino, M. A. Jr, Heinegard, D., Talal, N. & Wollheim, F. A. Detection of tumor-necrosis factor-\u03b1 but not tumor-necrosis factor-\u03b2 in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 31, 1041\u20131045 (1988).","journal-title":"Arthritis Rheum."},{"key":"BFnri802_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0896-8411(89)90129-7","volume":"2","author":"FM Brennan","year":"1989","unstructured":"Brennan, F. M., Chantry, D., Jackson, A. M., Maini, R. N. & Feldmann, M. Cytokine production in culture by cells isolated from the synovial membrane. J. Autoimmun. 2, 177\u2013186 (1989).","journal-title":"J. Autoimmun."},{"key":"BFnri802_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","volume":"14","author":"M Feldmann","year":"1996","unstructured":"Feldmann, M., Brennan, F. M. & Maini, R. N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397\u2013440 (1996).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnri802_CR23","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1084\/jem.162.4.1208","volume":"162","author":"J Saklatvala","year":"1985","unstructured":"Saklatvala, J., Sarsfield, S. J. & Townsend, Y. Purification of two immunologically different leucocyte proteins that cause cartilage resorption, lymphocyte activation and fever. J. Exp. Med. 162, 1208\u20131215 (1985).","journal-title":"J. Exp. Med."},{"key":"BFnri802_CR24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","volume":"2","author":"FM Brennan","year":"1989","unstructured":"Brennan, F. M., Chantry, D., Jackson, A., Maini, R. & Feldmann, M. Inhibitory effect of TNF-\u03b1 antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244\u2013247 (1989).","journal-title":"Lancet"},{"key":"BFnri802_CR25","first-page":"225","volume":"6","author":"DM Butler","year":"1995","unstructured":"Butler, D. M., Maini, R. N., Feldmann, M. & Brennan, F. M. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNF\u03b1 antibody with the IL-1 receptor antagonist. Eur. Cytokine Netw. 6, 225\u2013230 (1995).","journal-title":"Eur. Cytokine Netw."},{"key":"BFnri802_CR26","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.4049\/jimmunol.146.10.3365","volume":"146","author":"JM Alvaro-Garcia","year":"1991","unstructured":"Alvaro-Garcia, J. M., Zvaifler, N. J., Brown, C. B., Kaushansky, L. & Firestein, G. S. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte\u2013macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and TNF\u03b1. J. Immunol. 146, 3365\u20133371 (1991).","journal-title":"J. Immunol."},{"key":"BFnri802_CR27","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1002\/eji.1830211039","volume":"21","author":"C Haworth","year":"1991","unstructured":"Haworth, C., Brennan, F. M., Chantry, D., Turner, M., Maini, R. N. & Feldmann, M. Expression of granulocyte\u2013macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor-necrosis factor-\u03b1. Eur. J. Immunol. 21, 2575\u20132579 (1991).","journal-title":"Eur. J. Immunol."},{"key":"BFnri802_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1600-065X.1990.tb00817.x","volume":"118","author":"R Holmdahl","year":"1990","unstructured":"Holmdahl, R. et al. Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol. Rev. 118, 193\u2013232 (1990).","journal-title":"Immunol. Rev."},{"key":"BFnri802_CR29","doi-asserted-by":"publisher","first-page":"9784","DOI":"10.1073\/pnas.89.20.9784","volume":"89","author":"RO Williams","year":"1992","unstructured":"Williams, R. O., Feldmann, M. & Maini, R. N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA 89, 9784\u20139788 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri802_CR30","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1073\/pnas.89.16.7375","volume":"89","author":"GJ Thorbecke","year":"1992","unstructured":"Thorbecke, G. J. et al. Involvement of endogenous tumor-necrosis factor-\u03b1 and transforming growth factor-\u03b2 during induction of collagen type II arthritis in mice. Proc. Natl Acad. Sci. USA 89, 7375\u20137379 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri802_CR31","first-page":"510","volume":"77","author":"PF Piguet","year":"1992","unstructured":"Piguet, P. F. et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77, 510\u2013514 (1992).","journal-title":"Immunology"},{"key":"BFnri802_CR32","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1073\/pnas.89.2.673","volume":"89","author":"V Kruys","year":"1992","unstructured":"Kruys, V., Kemmer, K., Shakhov, A., Jongeneel, V. & Beutler, B. Constitutive activity of the tumor-necrosis factor promoter is cancelled by the 3\u2032 untranslated region in nonmacrophage cell lines; a transdominant factor overcomes this suppressive effect. Proc. Natl Acad. Sci. USA 89, 673\u2013677 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri802_CR33","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","volume":"10","author":"J Keffer","year":"1991","unstructured":"Keffer, J. et al. Transgenic mice expressing human tumour-necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025\u20134031 (1991).","journal-title":"EMBO J."},{"key":"BFnri802_CR34","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1084\/jem.174.6.1483","volume":"174","author":"K Peppel","year":"1991","unstructured":"Peppel, K., Crawford, D. & Beutler, B. A TNF receptor\u2013IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 174, 1483\u20131489 (1991).","journal-title":"J. Exp. Med."},{"key":"BFnri802_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/337525a0","volume":"337","author":"DJ Capon","year":"1989","unstructured":"Capon, D. J. et al. Designing CD4 immunoadhesions for AIDS therapy. Nature 337, 525\u2013531 (1989).","journal-title":"Nature"},{"key":"BFnri802_CR36","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","volume":"30","author":"DM Knight","year":"1993","unstructured":"Knight, D. M. et al. Construction and initial characterization of a mouse\u2013human chimeric anti-TNF antibody. Mol. Immunol. 30, 1443\u20131453 (1993).","journal-title":"Mol. Immunol."},{"key":"BFnri802_CR37","first-page":"480","volume":"49","author":"M Feldmann","year":"1990","unstructured":"Feldmann, M. et al. Cytokine production in the rheumatoid joint: implications for treatment. Ann. Rheum. Dis. 49, 480\u2013486 (1990).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnri802_CR38","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/art.1780361206","volume":"36","author":"MJ Elliott","year":"1993","unstructured":"Elliott, M. J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor-necrosis factor-\u03b1. Arthritis Rheum. 36, 1681\u20131690 (1993).","journal-title":"Arthritis Rheum."},{"key":"BFnri802_CR39","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S0140-6736(94)90632-7","volume":"344","author":"MJ Elliott","year":"1994","unstructured":"Elliott, M. J. et al. Repeated therapy with monoclonal antibody to tumour-necrosis factor-\u03b1 (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125\u20131127 (1994).","journal-title":"Lancet"},{"key":"BFnri802_CR40","first-page":"805","volume":"257","author":"J Oudin","year":"1963","unstructured":"Oudin, J. & Michel, M. A new form of allotype of rabbit \u03b3-globulins apparently correlated with antibody function and specificity. C. R. Acad. Sci. 257, 805\u2013808 (1963).","journal-title":"C. R. Acad. Sci."},{"key":"BFnri802_CR41","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini, R. N. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-\u03b1 monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552\u20131563 (1998).","journal-title":"Arthritis Rheum."},{"key":"BFnri802_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0065-2776(08)60466-6","volume":"8","author":"DW Dresser","year":"1968","unstructured":"Dresser, D. W. & Mitchison, N. A. The mechanism of immunological paralysis. Adv. Immunol. 8, 129\u2013181 (1968).","journal-title":"Adv. Immunol."},{"key":"BFnri802_CR43","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1073\/pnas.65.3.551","volume":"65","author":"JM Chiller","year":"1970","unstructured":"Chiller, J. M., Habicht, G. S. & Weigle, W. O. Cellular sites of immunologic unresponsiveness. Proc. Natl Acad. Sci. USA 65, 551\u2013556 (1970).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri802_CR44","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1073\/pnas.91.7.2762","volume":"91","author":"RO Williams","year":"1994","unstructured":"Williams, R. O., Mason, L. J., Feldmann, M. & Maini, R. N. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc. Natl Acad. Sci. USA 91, 2762\u20132766 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri802_CR45","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1172\/JCI2676","volume":"102","author":"L Genestier","year":"1998","unstructured":"Genestier, L. et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J. Clin. Invest. 102, 322\u2013328 (1998).","journal-title":"J. Clin. Invest."},{"key":"BFnri802_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","volume":"19","author":"M Feldmann","year":"2001","unstructured":"Feldmann, M. & Maini, R. N. Anti-TNF-\u03b1 therapy for rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163\u2013196 (2001).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnri802_CR47","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"RN Maini","year":"1999","unstructured":"Maini, R. N. et al. Randomised phase III trial of infliximab (chimeric anti-TNF-\u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate. Lancet 354, 1932\u20131939 (1999).","journal-title":"Lancet"},{"key":"BFnri802_CR48","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343, 1594\u20131602 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnri802_CR49","unstructured":"Lipsky, P. E. et al. 102-week clinical and radiological results from the ATTRACT trial: a two-year, randomized, controlled, phase III trial of infliximab (Remicade) in patients with active rheumatoid arthritis despite methotrexate. Arthritis Rheum. 47, S242 (2000)."},{"key":"BFnri802_CR50","unstructured":"Rankin, E. C. et al. A double-blind, placebo-controlled, ascending-dose trial of the recombinant humanised anti-TNF-\u03b1 antibody CDP571 in patients with rheumatoid arthritis (RA): a preliminary report. Arthritis Rheum. 37, S295 (1994)."},{"key":"BFnri802_CR51","first-page":"S242","volume":"39","author":"O Sander","year":"1996","unstructured":"Sander, O. et al. Neutralization of TNF by Lenercept (TNFR55\u2013IgG1,Ro 45-2081) in patients with rheumatoid arthritis treated for three months: results of a European phase II trial. Arthritis Rheum. 39, S242 (1996).","journal-title":"Arthritis Rheum."},{"key":"BFnri802_CR52","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJM199707173370301","volume":"337","author":"LW Moreland","year":"1997","unstructured":"Moreland, L. W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor-necrosis factor receptor (p75)\u2013Fc fusion protein. N. Engl. J. Med. 337, 141\u2013147 (1997).","journal-title":"N. Engl. J. Med."},{"key":"BFnri802_CR53","first-page":"1849","volume":"23","author":"LW Moreland","year":"1996","unstructured":"Moreland, L. W. et al. Recombinant soluble tumor-necrosis factor receptor (p80) fusion protein: toxicity and dose-finding trial in refractory rheumatoid arthritis. J. Rheumatol. 23, 1849\u20131855 (1996).","journal-title":"J. Rheumatol."},{"key":"BFnri802_CR54","doi-asserted-by":"publisher","first-page":"I70","DOI":"10.1136\/ard.58.2008.i70","volume":"58","author":"J Kempeni","year":"1999","unstructured":"Kempeni, J. Preliminary results of early clinical trials with the fully human anti-TNF monoclonal antibody D2E7. Ann. Rheum. Dis. 58, I70\u2013I72 (1999).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnri802_CR55","doi-asserted-by":"publisher","first-page":"I73","DOI":"10.1136\/ard.58.2008.i73","volume":"58","author":"CKI Edwards","year":"1999","unstructured":"Edwards, C. K. I. PEGylated recombinant human soluble tumour-necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases. Ann. Rheum. Dis. 58, I73\u201381 (1999).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnri802_CR56","first-page":"87","volume":"39","author":"B Hazleman","year":"2000","unstructured":"Hazleman, B. et al. Efficacy of a novel PEGylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid arthritis. Rheumatology 39, 87 (2000).","journal-title":"Rheumatology"},{"key":"BFnri802_CR57","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1002\/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F","volume":"43","author":"AK Ulfgren","year":"2000","unstructured":"Ulfgren, A. K. et al. Systemic anti-tumor necrosis factor-\u03b1 therapy in rheumatoid arthritis down-regulates synovial tumor-necrosis factor-\u03b1 synthesis. Arthritis Rheum. 43, 2391\u20132396 (2000).","journal-title":"Arthritis Rheum."},{"key":"BFnri802_CR58","doi-asserted-by":"crossref","first-page":"22027","DOI":"10.1016\/S0021-9258(17)31750-7","volume":"269","author":"S Lacraz","year":"1994","unstructured":"Lacraz, S., Isler, P., Vey, E., Welgus, H. G. & Dayer, J. M. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J. Biol. Chem. 269, 22027\u201322033 (1994).","journal-title":"J. Biol. Chem."},{"key":"BFnri802_CR59","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/art.1780390703","volume":"39","author":"EM Paleolog","year":"1996","unstructured":"Paleolog, E. M., Hunt, M., Elliott, M. J., Feldmann, M., Maini, R. N. & Woody, J. N. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor-\u03b1 antibody in rheumatoid arthritis. Arthritis Rheum. 39, 1082\u20131091 (1996).","journal-title":"Arthritis Rheum."},{"key":"BFnri802_CR60","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/1529-0131(200109)44:9<2055::AID-ART355>3.0.CO;2-2","volume":"44","author":"S Ballara","year":"2001","unstructured":"Ballara, S. et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 44, 2055\u20132064 (2001).","journal-title":"Arthritis Rheum."},{"key":"BFnri802_CR61","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/rheumatology\/36.9.950","volume":"36","author":"D Davis","year":"1997","unstructured":"Davis, D. et al. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor-\u03b1 blockade. Br. J. Rheumatol. 36, 950\u2013956 (1997).","journal-title":"Br. J. Rheumatol."},{"key":"BFnri802_CR62","first-page":"S117","volume":"42","author":"B Finck","year":"1999","unstructured":"Finck, B. et al. A phase III trial of etanercept versus methotrexate (MTX) in early rheumatoid arthritis (Enbrel ERA trial). Arthritis Rheum. 42, S117 (1999).","journal-title":"Arthritis Rheum."},{"key":"BFnri802_CR63","unstructured":"Rau, R. et al. Long-term treatment with the fully human anti-TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis. Arthritis Rheum. 42, S400 (1999)."},{"key":"BFnri802_CR64","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1146\/annurev.iy.07.040189.002203","volume":"7","author":"H Waldmann","year":"1989","unstructured":"Waldmann, H. Manipulation of T-cell responses with monoclonal antibodies. Annu. Rev. Immunol. 7, 407\u2013444 (1989).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnri802_CR65","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","volume":"109","author":"HM van Dulleman","year":"1995","unstructured":"van Dulleman, H. M. et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129\u2013135 (1995).","journal-title":"Gastroenterology"},{"key":"BFnri802_CR66","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present, D. H. et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340, 1398\u20131405 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnri802_CR67","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell, D. J. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342, 763\u2013769 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnri802_CR68","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","volume":"43","author":"J Brandt","year":"2000","unstructured":"Brandt, J. et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor-\u03b1 monoclonal antibody infliximab. Arthritis Rheum. 43, 1346\u20131352 (2000).","journal-title":"Arthritis Rheum."},{"key":"BFnri802_CR69","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease, P. J. et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356, 385\u2013390 (2000).","journal-title":"Lancet"},{"key":"BFnri802_CR70","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","volume":"357","author":"U Chaudhari","year":"2001","unstructured":"Chaudhari, U. et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357, 1842\u20131847 (2001).","journal-title":"Lancet"},{"key":"BFnri802_CR71","unstructured":"Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS\/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53, 444\u2013445 (1999)."},{"key":"BFnri802_CR72","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1172\/JCI117394","volume":"94","author":"AP Cope","year":"1994","unstructured":"Cope, A. P. et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T-cell receptor\/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J. Clin. Invest. 94, 749\u2013760 (1994).","journal-title":"J. Clin. Invest."},{"key":"BFnri802_CR73","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1161\/01.CIR.99.25.3224","volume":"99","author":"A Deswal","year":"1999","unstructured":"Deswal, A. et al. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced hear failure. Circulation 99, 3224\u20133226 (1999).","journal-title":"Circulation"},{"key":"BFnri802_CR74","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane, J. et al. Tuberculosis associated with Infliximab, a tumor-necrosis factor-\u03b1 neutralizing agent. N. Engl. J. Med. 345, 1098\u20131104 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnri802_CR75","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0065-2776(08)60891-3","volume":"64","author":"M Feldmann","year":"1997","unstructured":"Feldmann, M., Elliott, M. J., Woody, J. N. & Maini, R. N. Anti-tumor necrosis factor-\u03b1 therapy of rheumatoid arthritis. Adv. Immunol. 64, 283\u2013350 (1997).","journal-title":"Adv. Immunol."},{"key":"BFnri802_CR76","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1001\/jama.286.22.2787","volume":"286","author":"DS Pisetsky","year":"2001","unstructured":"Pisetsky, D. S. & St Clair, E. W. Progress in the treatment of rheumatoid arthritis. JAMA 286, 2787\u20132790 (2001).","journal-title":"JAMA"},{"key":"BFnri802_CR77","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S0140-6736(02)07718-8","volume":"359","author":"R Day","year":"2002","unstructured":"Day, R. Adverse reactions to TNF-\u03b1 inhibitors in rheumatoid arthritis. Lancet 359, 540\u2013541 (2002).","journal-title":"Lancet"},{"key":"BFnri802_CR78","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/1529-0131(200201)46:1<31::AID-ART10029>3.0.CO;2-5","volume":"46","author":"FM Brennan","year":"2002","unstructured":"Brennan, F. M. et al. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells. Arthritis Rheum. 46, 31\u201341 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnri802_CR79","first-page":"15","volume":"4","author":"P Isler","year":"1993","unstructured":"Isler, P., Vey, E., Zhang, J. H. & Dayer, J. M. Cell-surface glycoproteins expressed on activated human T cells induce production of interleukin\u20131\u03b2 by monocytic cells: a possible role of CD69. Eur. Cytokine Netw. 4, 15\u201323 (1993).","journal-title":"Eur. Cytokine Netw."},{"key":"BFnri802_CR80","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","volume":"344","author":"MJ Elliott","year":"1994","unstructured":"Elliott, M. J. et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour-necrosis factor-\u03b1 (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105\u20131110 (1994).","journal-title":"Lancet"},{"key":"BFnri802_CR81","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/art.1780330403","volume":"33","author":"HE Paulus","year":"1990","unstructured":"Paulus, H. E., Egger, M. J., Ward, J. R., Williams, H. J. & Cooperative Systemic Studies of Rheumatic Disease Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum. 33, 477\u2013484 (1990).","journal-title":"Arthritis Rheum."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nri802.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nri802","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nri802.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:38:06Z","timestamp":1684467486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nri802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["BFnri802"],"URL":"https:\/\/doi.org\/10.1038\/nri802","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}